Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Endocrinology. 2022 Oct 23;163(12). doi: 10.1210/endocr/bqac136.
Regulation of thyroid cells by thyrotropin (TSH) and epidermal growth factor (EGF) has been known but different effects of these regulators on proliferation and differentiation have been reported. We studied these responses in primary cultures of human thyroid cells to determine whether TSH receptor (TSHR) signaling may involve EGF receptor (EGFR) transactivation. We confirm that EGF stimulates proliferation and de-differentiation whereas TSH causes differentiation in the absence of other growth factors. We show that TSH/TSHR transactivates EGFR and characterize it as follows: (1) TSH-induced upregulation of thyroid-specific genes is inhibited by 2 inhibitors of EGFR kinase activity, AG1478 and erlotinib; (2) the mechanism of transactivation is independent of an extracellular EGFR ligand by showing that 2 antibodies, cetuximab and panitumumab, that completely inhibited binding of EGFR ligands to EGFR had no effect on transactivation, and by demonstrating that no EGF was detected in media conditioned by thyrocytes incubated with TSH; (3) TSH/TSHR transactivation of EGFR is different than EGFR activation by EGF by showing that EGF led to rapid phosphorylation of EGFR whereas transactivation occurred in the absence of receptor phosphorylation; (4) EGF caused downregulation of EGFR whereas transactivation had no effect on EGFR level; (5) EGF and TSH stimulation converged on the protein kinase B (AKT) pathway, because TSH, like EGF, stimulated phosphorylation of AKT that was inhibited by EGFR inhibitors; and (6) TSH-induced upregulation of thyroid genes was inhibited by the AKT inhibitor MK2206. Thus, TSH/TSHR causes EGFR transactivation that is independent of extracellular EGFR ligand and in part mediates TSH regulation of thyroid hormone biosynthetic genes.
促甲状腺激素(TSH)和表皮生长因子(EGF)对甲状腺细胞的调节作用早已为人所知,但这些调节剂对增殖和分化的影响却有所不同。我们研究了这些反应在人甲状腺细胞原代培养中的作用,以确定 TSH 受体(TSHR)信号是否可能涉及表皮生长因子受体(EGFR)的转激活。我们证实 EGF 刺激增殖和去分化,而 TSH 在没有其他生长因子的情况下引起分化。我们表明 TSH/TSHR 可转激活 EGFR,并对其进行了如下特征描述:(1)TSH 诱导的甲状腺特异性基因上调被 2 种 EGFR 激酶活性抑制剂 AG1478 和厄洛替尼抑制;(2)转激活的机制与细胞外 EGFR 配体无关,通过显示 2 种抗体,西妥昔单抗和帕尼单抗,完全抑制 EGFR 配体与 EGFR 的结合,对转激活没有影响,并证明甲状腺细胞与 TSH 孵育后条件培养基中未检测到 EGF;(3)TSH/TSHR 对 EGFR 的转激活与 EGF 激活 EGFR 不同,因为 EGF 导致 EGFR 的快速磷酸化,而转激活发生在受体磷酸化不存在的情况下;(4)EGF 导致 EGFR 的下调,而转激活对 EGFR 水平没有影响;(5)EGF 和 TSH 刺激在蛋白激酶 B(AKT)途径上汇聚,因为 TSH 像 EGF 一样,刺激 AKT 的磷酸化,而 EGFR 抑制剂抑制该磷酸化;(6)AKT 抑制剂 MK2206 抑制 TSH 诱导的甲状腺基因上调。因此,TSH/TSHR 导致 EGFR 的转激活,该激活与细胞外 EGFR 配体无关,部分介导 TSH 对甲状腺激素生物合成基因的调节。